Last reviewed · How we verify
NCT03970889: Klue
Real-time Reminders To Decrease Late or Missed Meal Boluses
NA trial testing Klue in Type1 Diabetes Mellitus in 24 participants. Completed in 30 March 2020.
19 March 2020
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 24 |
| Start date | 12 October 2018 |
| Primary completion | 19 March 2020 |
| Estimated completion | 30 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Klue
Conditions studied
- Type1 Diabetes Mellitus — all drugs for Type1 Diabetes Mellitus →
Sponsor
Stanford University
Who can join
13 and older, any sex, with Type1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is examining whether the Klue app is effective in detecting missed or late meal boluses in patients with Type 1 diabetes. The app is programmed onto an Apple Watch and will detect potential missed boluses from hand motion. It will send text alerts to the user asking if they have bolused. This is a pilot study and will assess whether there is a change in the number of missed meal boluses in the two weeks prior to each visit. If the findings are significant, this software can be integrated in future closed-loop algorithms for automatic insulin delivery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Smartwatch gesture-based meal reminders improve glycaemic control.
Corbett JP, Hsu L, Brown SA, Kollar L, et al · · 2022 · cited 22× · PMID 35491517 · DOI 10.1111/dom.14737
Verify or expand the search:
- PubMed search for NCT03970889
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type1 Diabetes Mellitus
Currently open trials in the same condition.
- NCT03945747 — MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus · active not recruiting
- NCT03369821 — EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study) · recruiting
- NCT03811470 — China Diabetes Registry by Metabolic Management Center · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03970889 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 2 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03970889.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing